Work

AMPLITUDE: A Phase 2/3 Adaptive Trial of Inaxaplin in APOL1-Mediated Kidney Disease

Year: 2024

Type: article

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20241x7qn0bv

Authors: Glenn M. Chertow, George Manos, Ogo I. Egbuna

Institutions: Stanford Medicine, Stanford University, Vertex Pharmaceuticals (United States)

Language: English

Topic: Renal Diseases and Glomerulopathies

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403830496

FWCI:

Cites:

Cited by:

Related to: 10